Apwack
pt 3 of 3



RN 155271-52-6 CAPLUS
CN 1H-Purine-2,6-dione, 8-[2-(2-bromo-4,5-dimethoxyphenyl)ethenyl]-1,3-diethyl-3,7-dihydro-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 155271-53-7 CAPLUS
CN 1H-Purine-2,6-dione, 8-[2-(2-bromo-4,5-dimethoxyphenyl)ethenyl]-1,3-diethyl-3,7-dihydro-7-methyl-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 155271-54-8 CAPLUS
CN 1H-Purine-2,6-dione, 8-[2-(4,5-dimethoxy-2-nitrophenyl)ethenyl]-1,3-diethyl-3,7-dihydro-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 155271-55-9 CAPLUS
CN 1H-Purine-2,6-dione, 8-[2-(4,5-dimethoxy-2-nitrophenyl)ethenyl]-1,3-diethyl-3,7-dihydro-7-methyl-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 155271-56-0 CAPLUS
CN 1H-Purine-2,6-dione, 1,3-diethyl-3,7-dihydro-8-[2-(3-methoxy-2-nitrophenyl)ethenyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 155271-57-1 CAPLUS
CN 1H-Purine-2,6-dione, 1,3-diethyl-3,7-dihydro-8-[2-(3-methoxy-2-nitrophenyl)ethenyl]-7-methyl-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 155271-58-2 CAPLUS
CN 1H-Purine-2,6-dione,
1,3-diethyl-8-[2-(3-fluorophenyl)ethenyl]-3,7-dihydro-
, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 155271-59-3 CAPLUS
CN 1H-Purine-2,6-dione,
1,3-diethyl-8-[2-(3-fluorophenyl)ethenyl]-3,7-dihydro-
7-methyl-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 155271-60-6 CAPLUS
CN 1H-Purine-2,6-dione, 8-[2-(3,5-dimethoxyphenyl)ethenyl]-1,3-diethyl-3,7-

dihydro-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 155271-61-7 CAPLUS
CN 1H-Purine-2,6-dione, 8-[2-(3,5-dimethoxyphenyl)ethenyl]-1,3-diethyl-3,7-dihydro-7-methyl-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 155271-62-8 CAPLUS
CN 1H-Purine-2,6-dione,
8-[2-(3-chlorophenyl)ethenyl]-1,3-diethyl-3,7-dihydro-
, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 155271-63-9 CAPLUS
CN 1H-Purine-2,6-dione,
8-[2-(3-chlorophenyl)ethenyl]-1,3-diethyl-3,7-dihydro-
7-methyl-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 155271-64-0 CAPLUS
CN 1H-Purine-2,6-dione,
1,3-diethyl-3,7-dihydro-8-(1-methyl-2-phenylethenyl)-
, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 155271-65-1 CAPLUS
CN 1H-Purine-2,6-dione, 1,3-diethyl-3,7-dihydro-7-methyl-8-(1-methyl-2-
phenylethenyl)-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 155271-66-2 CAPLUS
CN 1H-Purine-2,6-dione, 1,3-diethyl-3,7-dihydro-8-[2-[4-(trifluoromethyl)phenyl]ethenyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 155271-67-3 CAPLUS
CN 1H-Purine-2,6-dione, 1,3-diethyl-3,7-dihydro-7-methyl-8-[2-[4-(trifluoromethyl)phenyl]ethenyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 155271-68-4 CAPLUS
CN 1H-Purine-2,6-dione, 1,3-diethyl-8-(1-fluoro-2-phenylethenyl)-3,7-dihydro-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 155271-69-5 CAPLUS
CN 1H-Purine-2,6-dione,
1,3-diethyl-8-(1-fluoro-2-phenylethenyl)-3,7-dihydro-
7-methyl-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 155271-70-8 CAPLUS
CN 1H-Purine-2,6-dione,
8-[2-(4-bromophenyl)ethenyl]-1,3-diethyl-3,7-dihydro-
, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 155271-71-9 CAPLUS
CN 1H-Purine-2,6-dione,
8-[2-(4-bromophenyl)ethenyl]-1,3-diethyl-3,7-dihydro-
7-methyl-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 155271-72-0 CAPLUS
CN 1H-Purine-2,6-dione, 1,3-diethyl-3,7-dihydro-8-[2-[3-(trifluoromethoxy)phenyl]ethenyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 155271-73-1 CAPLUS
CN 1H-Purine-2,6-dione, 1,3-diethyl-3,7-dihydro-7-methyl-8-[2-[3-(trifluoromethoxy)phenyl]ethenyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 155271-74-2 CAPLUS
CN 1H-Purine-2,6-dione, 1,3-diethyl-3,7-dihydro-8-[2-[4-(methoxymethoxy)phenyl]ethenyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 155271-75-3 CAPLUS
CN 1H-Purine-2,6-dione, 1,3-diethyl-3,7-dihydro-8-[2-[4-(methoxymethoxy)phenyl]ethenyl]-7-methyl-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 155271-76-4 CAPLUS
CN 1H-Purine-2,6-dione, 1,3-diethyl-8-[2-(4-fluorophenyl)ethenyl]-3,7-dihydro-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 155271-77-5 CAPLUS
CN 1H-Purine-2,6-dione, 1,3-diethyl-8-[2-(4-fluorophenyl)ethenyl]-3,7-dihydro-7-methyl-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 155271-78-6 CAPLUS
CN 1H-Purine-2,6-dione, 8-[2-[3,5-bis(trifluoromethyl)phenyl]ethenyl]-1,3-diethyl-3,7-dihydro-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 155271-79-7 CAPLUS
CN 1H-Purine-2,6-dione, 8-[2-[3,5-bis(trifluoromethyl)phenyl]ethenyl]-1,3-diethyl-3,7-dihydro-7-methyl-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 155271-80-0 CAPLUS

CN 1H-Purine-2,6-dione, 8-[2-(3,5-difluorophenyl)ethenyl]-1,3-diethyl-3,7-dihydro-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 155271-81-1 CAPLUS
CN 1H-Purine-2,6-dione, 8-[2-(3,5-difluorophenyl)ethenyl]-1,3-diethyl-3,7-dihydro-7-methyl-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 155271-82-2 CAPLUS
CN 1H-Purine-2,6-dione,
1,3-diethyl-3,7-dihydro-8-[2-(3-nitrophenyl)ethenyl]-
, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 155271-83-3 CAPLUS
CN 1H-Purine-2,6-dione, 1,3-diethyl-3,7-dihydro-7-methyl-8-[2-(3-nitrophenyl)ethenyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 155271-84-4 CAPLUS
CN 1H-Purine-2,6-dione,
8-[2-(3-bromophenyl)ethenyl]-1,3-diethyl-3,7-dihydro-
, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 155271-85-5 CAPLUS
CN 1H-Purine-2,6-dione,
8-[2-(3-bromophenyl)ethenyl]-1,3-diethyl-3,7-dihydro-
7-methyl-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 155271-86-6 CAPLUS
CN 1H-Purine-2,6-dione, 1,3-diethyl-3,7-dihydro-8-[2-[3-(trifluoromethyl)phenyl]ethenyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 155271-87-7 CAPLUS
CN 1H-Purine-2,6-dione, 1,3-diethyl-3,7-dihydro-7-methyl-8-[2-[3-(trifluoromethyl)phenyl]ethenyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 155271-88-8 CAPLUS
CN 1H-Purine-2,6-dione, 8-[2-(6-bromo-1,3-benzodioxol-5-yl)ethenyl]-1,3-diethyl-3,7-dihydro-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 155271-89-9 CAPLUS
CN 1H-Purine-2,6-dione, 8-[2-(6-bromo-1,3-benzodioxol-5-yl)ethenyl]-1,3-diethyl-3,7-dihydro-7-methyl-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 155271-90-2 CAPLUS
CN 1H-Purine-2,6-dione, 1,3-diethyl-8-[2-(2-fluorophenyl)ethenyl]-3,7-dihydro-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 155271-91-3 CAPLUS
CN 1H-Purine-2,6-dione, 1,3-diethyl-8-[2-(2-fluorophenyl)ethenyl]-3,7-dihydro-7-methyl-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 155271-92-4 CAPLUS
CN 1H-Purine-2,6-dione, 8-[2-[4-(dimethylamino)phenyl]ethenyl]-1,3-diethyl-3,7-dihydro-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 155271-93-5 CAPLUS
CN 1H-Purine-2,6-dione, 8-(2-[1,1'-biphenyl]-4-ylethenyl)-1,3-diethyl-3,7-dihydro-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 155271-94-6 CAPLUS
CN 1H-Purine-2,6-dione, 8-(2-[1,1'-biphenyl]-4-ylethenyl)-1,3-diethyl-3,7-dihydro-7-methyl-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 155271-95-7 CAPLUS
CN 1H-Purine-2,6-dione, 1,3-diethyl-8-[2-(3-fluoro-4-methoxyphenyl)ethenyl]-3,7-dihydro-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 155271-96-8 CAPLUS
CN 1H-Purine-2,6-dione, 1,3-diethyl-8-[2-(3-fluoro-4-methoxyphenyl)ethenyl]-3,7-dihydro-7-methyl-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 155271-97-9 CAPLUS
CN 1H-Purine-2,6-dione, 8-[2-(3-chloro-4-fluorophenyl)ethenyl]-1,3-diethyl-3,7-dihydro-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 155271-98-0 CAPLUS
CN 1H-Purine-2,6-dione, 8-[2-(3-chloro-4-fluorophenyl)ethenyl]-1,3-diethyl-3,7-dihydro-7-methyl-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 155271-99-1 CAPLUS
CN 1H-Purine-2,6-dione, 1,3-diethyl-3,7-dihydro-8-[2-(7-methoxy-1,3-benzodioxol-5-yl)ethenyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 155272-00-7 CAPLUS
CN 1H-Purine-2,6-dione, 1,3-diethyl-3,7-dihydro-8-[(1E)-2-(7-methoxy-1,3-benzodioxol-5-yl)ethenyl]-7-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 155272-01-8 CAPLUS
CN 1H-Purine-2,6-dione, 1,3-diethyl-8-[2-(3-fluoro-2-methylphenyl)ethenyl]-3,7-dihydro-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 155272-02-9 CAPLUS
CN 1H-Purine-2,6-dione, 1,3-diethyl-8-[2-(3-fluoro-2-methylphenyl)ethenyl]-3,7-dihydro-7-methyl-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 155272-03-0 CAPLUS
CN 1H-Purine-2,6-dione, 8-[2-(3,4-dihydroxyphenyl)ethenyl]-1,3-diethyl-3,7-dihydro-7-methyl-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 155272-04-1 CAPLUS
CN 1H-Purine-2,6-dione, 1,3-diethyl-3,7-dihydro-8-[2-(3-hydroxy-4-methoxyphenyl)ethenyl]-7-methyl-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 155272-05-2 CAPLUS
CN 1H-Purine-2,6-dione, 1,3-diethyl-3,7-dihydro-8-[2-(4-hydroxyphenyl)ethenyl]-7-methyl-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 155272-06-3 CAPLUS
CN 1H-Purine-2,6-dione, 1,3-diethyl-3,7-dihydro-7-methyl-8-[2-[4-(phenylmethoxy)phenyl]ethenyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 155272-07-4 CAPLUS
CN 1H-Purine-2,6-dione, 8-[2-[4-(4-bromobutoxy)phenyl]ethenyl]-1,3-diethyl-3,7-dihydro-7-methyl-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 155272-08-5 CAPLUS
CN 1H-Purine-2,6-dione, 8-[2-[4-(4-azidobutoxy)phenyl]ethenyl]-1,3-diethyl-3,7-dihydro-7-methyl-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 155272-09-6 CAPLUS
CN 1H-Purine-2,6-dione, 8-[2-[4-(4-aminobutoxy)phenyl]ethenyl]-1,3-diethyl-3,7-dihydro-7-methyl-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 155272-10-9 CAPLUS
CN Acetic acid, [4-[2-(1,3-diethyl-2,3,6,7-tetrahydro-7-methyl-2,6-dioxo-1H-purin-8-yl)ethenyl]phenoxy]-, ethyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 155272-11-0 CAPLUS
CN Acetic acid, [4-[2-(1,3-diethyl-2,3,6,7-tetrahydro-7-methyl-2,6-dioxo-1H-purin-8-yl)ethenyl]phenoxy]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 155272-12-1 CAPLUS
CN 1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl-8-[2-(3-phenoxyphenyl)ethenyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 155272-13-2 CAPLUS
CN 1H-Purine-2,6-dione, 3,7-dihydro-1,3,7-trimethyl-8-[2-(3-phenoxyphenyl)ethenyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 155272-14-3 CAPLUS
CN 1H-Purine-2,6-dione, 1,3-diethyl-3,7-dihydro-8-[2-(4-hydroxyphenyl)ethenyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 155272-15-4 CAPLUS
CN 1H-Purine-2,6-dione, 1,3-diethyl-3,7-dihydro-8-[2-(4-hydroxy-2,3-dimethylphenyl)ethenyl]-7-methyl-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L22 ANSWER 49 OF 57 CAPLUS COPYRIGHT 2001 ACS
1995:168999 Document No. 122:81388 (Styryl)xanthine-derivatives adenosine A2
receptor antagonists. Suzuki, Fumio; Shimada, Junichi; Koike, Nobuaki; Kase, Hiroshi; Nakamura, Joji; Shiozaki, Shizaki; Nonaka, Hiromi (Kyowa Hakko Kogyo Co., Ltd., Japan). Can. Pat. Appl. CA 2112031 AA 19940625, 69 pp. (English). CODEN: CPXXEB. APPLICATION: CA 1993-2112031 19931221. PRIORITY: JP 1992-344116 19921224.

GI



I

AB The title compds. [I; Q1-Q3 = H, lower alkyl, lower alkoxy, halogen; R1-R3 = H, lower alkyl; X = COR4, SO2R5; R4 = H, HO, lower alkyl, lower alkoxy; R5 = (un)substituted NH2, etc.], useful as adenosine A2 receptor antagonists for the treatment of **Parkinson**'s disease (no data), depression (no data), etc., are prepd. and I-contg. formulations presented. Thus, (E)-8-(3-acetylstyryl)-1,3-diethyl-7-methylxanthine, m.p. 221.4-221.8.degree., was prepd. and demonstrated 85% inhibition. of 3H-CGS 21680 binding to rat brain-derived adenosine A2 receptors at 10-7 mol (Ki = 13 nM).

IT **160434-09-3P 160434-10-6P 160434-11-7P**
160434-12-8P 160434-14-0P 160434-15-1P
160434-16-2P 160434-17-3P 160434-18-4P
160434-19-5P 160434-20-8P 160434-21-9P
160434-23-1P 160434-24-2P 160434-25-3P
160434-26-4P 160434-27-5P 160434-28-6P
160434-29-7P 160434-30-0P 160434-31-1P

160434-32-2P 160434-33-3P 160434-34-4P
160434-35-5P 160434-36-6P 160434-37-7P
160434-38-8P 160434-39-9P 160434-40-2P
160471-61-4P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(styrylxanthine adenosine A2 receptor antagonists)

RN 160434-09-3 CAPLUS
CN Benzenesulfonic acid, 4,5-dimethoxy-2-[2-(2,3,6,7-tetrahydro-7-methyl-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)ethenyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 160434-10-6 CAPLUS
CN Benzenesulfonamide, N,N-diethyl-4,5-dimethoxy-2-[2-(2,3,6,7-tetrahydro-7-methyl-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)ethenyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 160434-11-7 CAPLUS
CN Benzenesulfonamide, 4,5-dimethoxy-N,N-dipropyl-2-[2-(2,3,6,7-tetrahydro-7-methyl-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)ethenyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 160434-12-8 CAPLUS
CN Piperidine,
1-[[4,5-dimethoxy-2-[2-(2,3,6,7-tetrahydro-7-methyl-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)ethenyl]phenyl]sulfonyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 160434-14-0 CAPLUS
CN Piperazine, 1-[[4,5-dimethoxy-2-[(1E)-2-(2,3,6,7-tetrahydro-7-methyl-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)ethenyl]phenyl]sulfonyl]-4-methyl-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 160434-13-9
CMF C27 H38 N6 O6 S
CDES 2:E

Double bond geometry as shown.



CM 2

CRN 110-17-8
CMF C4 H4 O4
CDES 2:E

Double bond geometry as shown.



RN 160434-15-1 CAPLUS
CN Benzenesulfonamide,
N-[2-(dimethylamino)ethyl]-4,5-dimethoxy-N-methyl-2-[2-

(2,3,6,7-tetrahydro-7-methyl-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)ethenyl]-
, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 160434-16-2 CAPLUS
CN Benzoic acid,
4-[2-(2,3,6,7-tetrahydro-7-methyl-2,6-dioxo-1,3-dipropyl-1H-

purin-8-yl)ethenyl]-, methyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 160434-17-3 CAPLUS
CN Benzoic acid,
4-[2-(2,3,6,7-tetrahydro-7-methyl-2,6-dioxo-1,3-dipropyl-1H-
purin-8-yl)ethenyl]-, methyl ester, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 160434-18-4 CAPLUS
CN Benzenesulfonamide, 4,5-dimethoxy-2-[2-(2,3,6,7-tetrahydro-7-methyl-2,6-
dioxo-1,3-dipropyl-1H-purin-8-yl)ethenyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 160434-19-5 CAPLUS
CN Benzenesulfonamide, 4,5-dimethoxy-N-phenyl-2-[2-(2,3,6,7-tetrahydro-7-methyl-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)ethenyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 160434-20-8 CAPLUS
CN Benzenesulfonic acid, 2,3,4-trimethoxy-6-[2-(2,3,6,7-tetrahydro-7-methyl-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)ethenyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 160434-21-9 CAPLUS
CN Benzenesulfonamide,
2,3,4-trimethoxy-6-[2-(2,3,6,7-tetrahydro-7-methyl-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)ethenyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 160434-23-1 CAPLUS
CN Benzenesulfonamide,
N-[2-(dimethylamino)ethyl]-2,3,4-trimethoxy-N-methyl-6-[(1E)-2-(2,3,6,7-tetrahydro-7-methyl-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)ethenyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 160434-22-0
CMF C28 H42 N6 O7 S
CDES 2:E

Double bond geometry as shown.



CM 2

CRN 110-17-8
CMF C4 H4 O4
CDES 2:E

Double bond geometry as shown.



RN 160434-24-2 CAPLUS
CN Benzenesulfonamide, N-(2-hydroxyethyl)-4,5-dimethoxy-2-[2-(2,3,6,7-tetrahydro-7-methyl-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)ethenyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 160434-25-3 CAPLUS
CN Benzenesulfonic acid, 4,5-dimethyl-2-[2-(2,3,6,7-tetrahydro-7-methyl-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)ethenyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 160434-26-4 CAPLUS
CN Benzenesulfonic acid, 2-[2-(1,3-diethyl-2,3,6,7-tetrahydro-7-methyl-2,6-dioxo-1H-purin-8-yl)ethenyl]-4-methoxy-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 160434-27-5 CAPLUS
CN Benzenesulfonamide, 2-[2-(1,3-diethyl-2,3,6,7-tetrahydro-7-methyl-2,6-dioxo-1H-purin-8-yl)ethenyl]-4-methoxy-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 160434-28-6 CAPLUS
CN Benzoic acid,
4-[2-(2,3,6,7-tetrahydro-7-methyl-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)ethenyl]-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 160434-29-7 CAPLUS
CN Benzoic acid,
4-[2-(2,3,6,7-tetrahydro-7-methyl-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)ethenyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 160434-30-0 CAPLUS
CN Benzoic acid, 3-methoxy-4-[2-(2,3,6,7-tetrahydro-7-methyl-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)ethenyl]-, methyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 160434-31-1 CAPLUS
CN Benzoic acid, 4-[2-(1,3-diethyl-2,3,6,7-tetrahydro-7-methyl-2,6-dioxo-1H-purin-8-yl)ethenyl]-3-methoxy-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 160434-32-2 CAPLUS
CN Benzoic acid, 3-methoxy-4-[2-(2,3,6,7-tetrahydro-7-methyl-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)ethenyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 160434-33-3 CAPLUS
CN 1H-Purine-2,6-dione,
8-[2-(3-acetylphenyl)ethenyl]-1,3-diethyl-3,7-dihydro-7-methyl-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 160434-34-4 CAPLUS
CN Benzoic acid, 3-[2-(1,3-diethyl-2,3,6,7-tetrahydro-7-methyl-2,6-dioxo-1H-purin-8-yl)ethenyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 160434-35-5 CAPLUS
CN 1H-Purine-2,6-dione,
8-[2-(3-acetyl-4-methoxyphenyl)ethenyl]-3,7-dihydro-7-methyl-1,3-dipropyl-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 160434-36-6 CAPLUS
CN Benzoic acid, 2-methoxy-5-[2-(2,3,6,7-tetrahydro-7-methyl-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)ethenyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 160434-37-7 CAPLUS
CN 1H-Purine-2,6-dione, 8-[2-(3-acetyl-4-fluorophenyl)ethenyl]-1,3-diethyl-3,7-dihydro-7-methyl-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 160434-38-8 CAPLUS
CN Benzoic acid, 5-[2-(1,3-diethyl-2,3,6,7-tetrahydro-7-methyl-2,6-dioxo-1H-purin-8-yl)ethenyl]-2-fluoro-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 160434-39-9 CAPLUS
CN 1H-Purine-2,6-dione, 8-[2-(4-acetyl-3-methoxyphenyl)ethenyl]-1,3-diethyl-3,7-dihydro-7-methyl-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 160434-40-2 CAPLUS
CN Benzenesulfonic acid,
4-[(1E)-2-(2,3,6,7-tetrahydro-7-methyl-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)ethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 160471-61-4 CAPLUS
CN Benzoic acid, 4-[2-(1,3-diethyl-2,3,6,7-tetrahydro-7-methyl-2,6-dioxo-1H-purin-8-yl)ethenyl]-3-methoxy-, methyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT **141807-86-5**, (E)-1,3-Dipropyl-7-methyl-8-styrylxanthine
141807-96-7 141807-98-9

RL: RCT (Reactant)
(styrylxanthine adenosine A2 receptor antagonists)

RN 141807-86-5 CAPLUS
CN 1H-Purine-2,6-dione,
3,7-dihydro-7-methyl-8-(2-phenylethenyl)-1,3-dipropyl-
, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 141807-96-7 CAPLUS
CN 1H-Purine-2,6-dione,
8-[(1E)-2-(3,4-dimethoxyphenyl)ethenyl]-3,7-dihydro-7-
methyl-1,3-dipropyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 141807-98-9 CAPLUS
CN 1H-Purine-2,6-dione, 3,7-dihydro-7-methyl-1,3-dipropyl-8-[2-(3,4,5-
trimethoxyphenyl)ethenyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT **151539-48-9P 151539-50-3P 155271-32-2P**
155271-33-3P 155271-84-4P 155271-85-5P
160434-22-0P 160434-44-6P 160434-45-7P
160434-46-8P 160434-47-9P 160434-48-0P
160441-79-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(styrylxanthine adenosine A2 receptor antagonists)
RN 151539-48-9 CAPLUS
CN 1H-Purine-2,6-dione, 8-[2-(3-bromo-4-methoxyphenyl)ethenyl]-3,7-dihydro-1,3-dipropyl-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 151539-50-3 CAPLUS
CN 1H-Purine-2,6-dione,
8-[2-(3-bromo-4-methoxyphenyl)ethenyl]-3,7-dihydro-7-methyl-1,3-dipropyl-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 155271-32-2 CAPLUS
CN 1H-Purine-2,6-dione, 1,3-diethyl-3,7-dihydro-8-[2-(3-methoxyphenyl)ethenyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 155271-33-3 CAPLUS
CN 1H-Purine-2,6-dione, 1,3-diethyl-3,7-dihydro-8-[2-(3-methoxyphenyl)ethenyl]-7-methyl-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 155271-84-4 CAPLUS
CN 1H-Purine-2,6-dione,
8-[2-(3-bromophenyl)ethenyl]-1,3-diethyl-3,7-dihydro-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 155271-85-5 CAPLUS
CN 1H-Purine-2,6-dione,
8-[2-(3-bromophenyl)ethenyl]-1,3-diethyl-3,7-dihydro-
7-methyl-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 160434-22-0 CAPLUS
CN Benzenesulfonamide,
N-[2-(dimethylamino)ethyl]-2,3,4-trimethoxy-N-methyl-6-
[2-(2,3,6,7-tetrahydro-7-methyl-2,6-dioxo-1,3-dipropyl-1H-purin-8-
yl)ethenyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 160434-44-6 CAPLUS
CN 1H-Purine-2,6-dione,
8-[2-(3-bromo-4-fluorophenyl)ethenyl]-1,3-diethyl-3,7-
dihydro-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 160434-45-7 CAPLUS
CN 1H-Purine-2,6-dione,
8-[2-(3-bromo-4-fluorophenyl)ethenyl]-1,3-diethyl-3,7-
dihydro-7-methyl-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 160434-46-8 CAPLUS
CN 1H-Purine-2,6-dione, 1,3-diethyl-3,7-dihydro-8-[2-[3-methoxy-4-
(methoxymethoxy)phenyl]ethenyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 160434-47-9 CAPLUS
CN 1H-Purine-2,6-dione, 1,3-diethyl-3,7-dihydro-8-[2-[3-methoxy-4-(methoxymethoxy)phenyl]ethenyl]-7-methyl-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 160434-48-0 CAPLUS
CN 1H-Purine-2,6-dione, 1,3-diethyl-3,7-dihydro-8-[2-(4-hydroxy-3-methoxyphenyl)ethenyl]-7-methyl-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 160441-79-2 CAPLUS
CN Methanesulfonic acid, trifluoro-, 4-[2-(1,3-diethyl-2,3,6,7-tetrahydro-7-methyl-2,6-dioxo-1H-purin-8-yl)ethenyl]-2-methoxyphenyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L22 ANSWER 50 OF 57 CAPLUS COPYRIGHT 2001 ACS DUPLICATE 5
1994:315658 Document No. 120:315658 KF17837: a novel selective adenosine A2A
receptor antagonist with anticataleptic activity. Kanda, Tomoyuki; Shiozaki, Shizuo; Shimada, Junichi; Suzuki, Fumio; Nakamura, Joji (Pharmaceutical Research Laboratories, Kyowa Hakko Kogyo Co. Ltd., 1188 Shimotogari, Nagaizumi-Cho, Sunto-Gun, Shizuoka, 411, Japan). Eur. J. Pharmacol., 256(3), 263-8 (English) 1994. CODEN: EJPHAZ. ISSN: 0014-2999.

AB KF17837 is a novel selective adenosine A2A receptor antagonist. Oral administration of KF17837 (2.5, 10.0 and 30.0 mg/kg) significantly ameliorated the cataleptic responses induced by intracerebroventricular administration of an adenosine A2A receptor agonist, CGS 21680 (10 .mu.g), in a dose-dependent manner. KF17837 also reduced the catalepsy induced by haloperidol (1 mg/kg i.p.) and by reserpine (5 mg/kg i.p.). These anticataleptic effects were exhibited dose dependently at doses from 0.625 and 2.5 mg/kg p.o., resp. Moreover, KF17837 (0.625 mg/kg p.o.) potentiated the anticataleptic effects of a subthreshold dose of L-3,4-dihydroxyphenylalanine (L-DOPA; 25 mg/kg i.p.) plus benserazide (6.25 mg/kg i.p.). These results suggested that KF17837 is a centrally active adenosine A2A receptor antagonist and that the dopaminergic function of the nigrostriatal pathway is potentiated by adenosine A2A receptor antagonists. Furthermore, KF17837 may be a useful drug in the treatment of **parkinsonism**.

IT **141807-96-7**, KF17837
RL: BIOL (Biological study)
(adenosine A2A receptor antagonist, dopaminergic function potentiation by, anticataleptic effects in relation to)

RN 141807-96-7 CAPLUS

CN 1H-Purine-2,6-dione, 8-[(1E)-2-(3,4-dimethoxyphenyl)ethenyl]-3,7-dihydro-7-methyl-1,3-dipropyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L22 ANSWER 51 OF 57 CAPLUS COPYRIGHT 2001 ACS
1994:144161 Document No. 120:144161 Pharmaceutical compositions containing

xanthine derivatives for treatment of **Parkinson**'s disease.
Suzuki, Fumio; Shimada, Junichi; Ishii, Akio; Ichikawa, Shunji (Kyowa Hakko Kogyo Co., Ltd., Japan). Eur. Pat. Appl. EP 565377 A1 19931013, 49 pp. DESIGNATED STATES: R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE. (English). CODEN: EPXXDW. APPLICATION: EP 1993-302780 19930408. PRIORITY: JP 1992-87115 19920408.

GI



I

AB Pharmaceutical compns. contg. xanthine derivs. (I; R1, R2, R3=H, C1-6 alkyl or allyl; R4= C3-8 cycloalkyl) are useful for treatment of **Parkinson**'s disease. (E)-6-amino-5-(3,4-dimethyoxycinnamoyl)amino-1,3-dipropyluracil (prepn. is given) was refluxed in NaOH soln., then was neutralized and the deposited crysts. were sepd. to to obtain (E)-8-(3,4-dimethyoxstyryl)-1,3-dipropylxanthine (II). To II in DMF was added K2CO3 and MeI and the mixt. was heated at 50.degree. for 30min followed by filteration and addn. of water. The filtrate was extd. with CHCl3 and the ext. was washed, dried, evapd., and purified to obtain (E)-8-(3,4-dimethyoxystyryl)-7-methyl-1,3-dipropylxantha=ine (III). A tablet contained III 20, lactose 143.4, potato starch 30, hydroxypropyl cellulose 6, and Mg stearate 0.6mg.

IT **132940-42-2P 141807-95-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and reaction of)

RN 132940-42-2 CAPLUS
CN 1H-Purine-2,6-dione, 3,7-dihydro-8-[(1E)-2-phenylethenyl]-1,3-dipropyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 141807-95-6 CAPLUS
CN 1H-Purine-2,6-dione, 8-[(1E)-2-(3,4-dimethoxyphenyl)ethenyl]-3,7-dihydro-

1,3-dipropyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT **141807-86-5P 141807-94-5P 141807-96-7P**
141807-97-8P 141807-98-9P 142665-35-8P
142665-36-9P 142665-38-1P 147700-41-2P
147700-43-4P 147700-44-5P 147700-45-6P
147700-46-7P 147700-47-8P 147700-51-4P
147700-52-5P 147700-53-6P 147700-54-7P
151539-17-2P 151539-19-4P 151539-20-7P
151539-21-8P 151539-22-9P 151539-23-0P
151539-24-1P 151539-26-3P 151539-27-4P
151539-28-5P 151539-29-6P 151539-30-9P
151539-31-0P 151539-32-1P 151539-33-2P
151539-34-3P 151539-35-4P 151539-36-5P
151539-37-6P 151539-39-8P 151539-40-1P
151539-41-2P 151539-42-3P 151539-43-4P
151539-44-5P 151539-45-6P 151539-46-7P
151539-47-8P 151539-48-9P 151539-50-3P
151539-51-4P 151539-53-6P 151539-54-7P
151539-56-9P 151539-57-0P 151539-58-1P
151539-60-5P 151539-61-6P 151539-62-7P
151539-63-8P 151539-65-0P 151539-68-3P
RL: PREP (Preparation)
(prepn. of, pharmaceutical compn. contg., for treatment of **Parkinson**'s disease)

RN 141807-86-5 CAPLUS

CN 1H-Purine-2,6-dione, 3,7-dihydro-7-methyl-8-(2-phenylethenyl)-1,3-dipropyl-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 141807-94-5 CAPLUS
CN 1H-Purine-2,6-dione, 3,7-dihydro-8-[2-(4-methoxyphenyl)ethenyl]-7-methyl-1,3-dipropyl-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 141807-96-7 CAPLUS
CN 1H-Purine-2,6-dione, 8-[(1E)-2-(3,4-dimethoxyphenyl)ethenyl]-3,7-dihydro-7-methyl-1,3-dipropyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 141807-97-8 CAPLUS
CN 1H-Purine-2,6-dione, 3,7-dihydro-1,3-dipropyl-8-[2-(3,4,5-trimethoxyphenyl)ethenyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 141807-98-9 CAPLUS
CN 1H-Purine-2,6-dione, 3,7-dihydro-7-methyl-1,3-dipropyl-8-[2-(3,4,5-trimethoxyphenyl)ethenyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 142665-35-8 CAPLUS
CN 1H-Purine-2,6-dione, 3,7-dihydro-1,3-di-2-propenyl-8-[2-(3,4,5-trimethoxyphenyl)ethenyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 142665-36-9 CAPLUS
CN 1H-Purine-2,6-dione, 3,7-dihydro-7-methyl-1,3-di-2-propenyl-8-[(1E)-2-(3,4,5-trimethoxyphenyl)ethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 142665-38-1 CAPLUS
CN 1H-Purine-2,6-dione, 1,3-dibutyl-3,7-dihydro-7-methyl-8-[2-(3,4,5-trimethoxyphenyl)ethenyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 147700-41-2 CAPLUS
CN 1H-Purine-2,6-dione, 3,7-dihydro-7-methyl-8-[2-(3-nitrophenyl)ethenyl]-1,3-dipropyl-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 147700-43-4 CAPLUS
CN 1H-Purine-2,6-dione, 8-[2-(3-fluorophenyl)ethenyl]-3,7-dihydro-1,3-dipropyl-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 147700-44-5 CAPLUS
CN 1H-Purine-2,6-dione, 8-[2-(3-fluorophenyl)ethenyl]-3,7-dihydro-7-methyl-1,3-dipropyl-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

<------User Break------>
u
=> d l22 52-57 cbiba bs
'CBIBA' IS NOT A VALID FORMAT
'BS' IS NOT A VALID FORMAT
In a multifile environment, a format can only be used if it is valid
in at least one of the files. Refer to file specific help messages
or the STNGUIDE file for information on formats available in
individual files.
REENTER DISPLAY FORMAT FOR ALL FILES (FILEDEFAULT):cbib abs

L22 ANSWER 52 OF 57 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.
94106081 EMBASE Document No.: 1994106081. S9977-2 reduces learning impairment
and brain interleukin-1.beta. overproduction in rats with neurotoxic lesions in the nucleus basalis of Meynert. Alvarez X.A.; Franco A.; Rettori M.-C.; Kamoun A.; Polo E.; Cacabelos R.. Institute for CNS Disorders, Basic/Clin. Neurosciences Res. Ctr.,A Coruna, Spain. European

Neuropsychopharmacology 3/3 (425-426) 1993.
ISSN: 0924-977X. CODEN: EURNE8. Pub. Country: Netherlands. Language: English.

L22 ANSWER 53 OF 57 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.
93017781 EMBASE Document No.: 1993017781. **Alzheimer**'s disease: News and prospects. Cacabelos R.. Institute for CNS Disorders, Basic/Clinical Neurosc Research Cent,La Coruna, Spain. Drug News and Perspectives 5/8 (501-506) 1992.
ISSN: 0214-0934. CODEN: DNPEED. Pub. Country: Spain. Language: English.

L22 ANSWER 54 OF 57 BIOSIS COPYRIGHT 2001 BIOSIS
1992:491678 Document No.: BR43:100878. SELECTIVE INHIBITION OF HUMAN ACETYLCHOLINESTERASE IN-VITRO BY S-9977-2. THOMSEN T. INST. CLIN. PHARMACOL., KLINIKUM STEGLITZ, FREE UNIV. BERLIN, D-1000 BERLIN 45, GER.. THIRD INTERNATIONAL CONFERENCE ON ALZHEIMER'S DISEASE AND RELATED DISORDERS, ABANO TERME, ITALY, JULY 12-17, 1992. NEUROBIOL AGING. (1992) 13 (SUPPL 1), S132. CODEN: NEAGDO. ISSN: 0197-4580. Language: English.

L22 ANSWER 55 OF 57 CAPLUS COPYRIGHT 2001 ACS
1992:483453 Document No. 117:83453 1,3,7-Trimethyl-8-[3-(4-diethylaminocarbonylpiperazino)propyl]xanthine for treatment of memory disorders, intellectual disorders of ageing, and **Alzheimer**'s disease. Kamoun, Annie; Mocaer, Elisabeth; Regnier, Gilbert; Guillonneau, Claude; Duhault, Jacques (ADIR et Cie., Fr.). S. African ZA 9007739 A 19910731, 18 pp. (English). CODEN: SFXXAB. APPLICATION: ZA 1990-7739 19900927. PRIORITY: FR 1990-10235 19900810.
AB The title compd. (I), and its physiol. tolerable acid addn. salts are used for treatment of memory disorders, intellectual disorders of aging, and **Alzheimer**'s disease. In animal testing, I-HCl improved spontaneous alteration, acquisition, and retention (24 h later) of spatial discrimination in a T-shaped labyrinth. The effect of I-HCl on memory retention and on amnesia are also described.

L22 ANSWER 56 OF 57 CAPLUS COPYRIGHT 2001 ACS
1991:102033 Document No. 114:102033 Preparation of 1,3-dialkyl-8-substituted-xanthines as drugs. Maschler, Harald; Spicer, Barbara Ann; Smith, Harry (Beecham-Wuelfing G.m.b.H. und Co. K.-G., Fed. Rep. Ger.; Beecham Group PLC). Eur. Pat. Appl. EP 389282 A2 19900926, 24 pp. DESIGNATED STATES: R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE. (English). CODEN: EPXXDW. APPLICATION: EP 1990-303093 19900322. PRIORITY: GB 1989-6792 19890323.
GI



I

AB The title compds. [I; R1,R2 = alkyl, (CH2)mA; m = 1-3; A = (substituted) cyclic hydrocarbyl; R3 = halo, NO2, amino, acylamino], were prepd. Thus, 1,3-dibutylxanthine in HOAc was treated with conc. HNO3 at 87.degree. to give 86% 1,3-dibutyl-8-nitroxanthine. The latter in conc. HCl was treated with Sn to give 63% 1,3-dibutyl-8-aminoxanthine hydrochloride. The latter inhibited cAMP phosphodiesterase with Ki = 1.3 .mu.M.

L22 ANSWER 57 OF 57 CAPLUS COPYRIGHT 2001 ACS

1991:164265 Document No. 114:164265 Preparation of xanthines as adenosine antagonists. Kuefner-Muehl, Ulrike; Weber, Karl Heinz; Walther, Gerhard; Stransky, Werner; Ensinger, Helmut; Schingnitz, Guenter; Kuhn, Franz Josef; Lehr, Erich (Boehringer Ingelheim K.-G., Fed. Rep. Ger.). Ger. Offen. DE 3843117 A1 19900628, 20 pp. (German). CODEN: GWXXBX. APPLICATION: DE 1988-3843117 19881222.

GI



I Q Q1

AB The title compds. [I; R1 = C1-6 alkyl, C3-4 alkenyl or alkynyl; R2 = H, C1-6 alkyl, C3-4 alkenyl or alkynyl, (un)substituted benzyl; R3 = C-attached (un)satd. 5-, 6-, or 7-membered heterocycle contg. .gtoreq.1 O, S, and optionally substituted by C1-6 alkyl, CHO, CH2OR4, CO2R4, CONR5R6, etc., C4-8 cycloalkyl, (un)substituted C3-8 cycloalkane, (un)substituted C4-8 cycloalkanone or cycloalkanol, C6H3R7R8-3,4, fluorenyl, bicyclyl residues Q, Q1, etc.; R4 = H, C1-13 alkyl, propargyl, etc.; R5 = H, C1-6 alkyl, etc.; R6 = H, C1-6 alkyl, PhCH2, etc.; R7R8 = OCH2O, OCH2CH2O] and their pharmacol. unobjectionable salts, adenosine antagonists having a specific affinity for the A1 receptor-subtype, useful for the treatment of the ageing-related illnesses, e.g., senile dementia and **Alzheimer**'s disease, were prepd. A soln. of 2.9 g 1-benzyl-3-propyl-5-nitroso-6-aminouracil, prepd. by N-propylation of 1-benzyl-6-aminouracil followed by

```
     nitrosation, and 2.3 g 1,4-benzodioxane-6-aldehyde in DMF was treated
with
     0.5 g Me2NNH2 and the mixt. was refluxed 8 h to give 1 g I (R1 = PhCH2,
R2
     = Pr, R3 = 1,4-benzodioxin-6-yl).  The Ki of 9 I for the adenosine A1
     receptor were 2 .times. 10-9 to 8 .times. 10-9 nM and >1 .times. 10-5 to
9
     .times. 10-5 nM for the A2 receptor.


=> dis his

     (FILE 'CAOLD' ENTERED AT 14:28:39 ON 04 SEP 2001)
                DEL HIS Y

     FILE 'REGISTRY' ENTERED AT 14:31:10 ON 04 SEP 2001
L1                STR
L2             41 S L1
L3                STR L1
L4           1960 S L1 FUL

     FILE 'CAPLUS' ENTERED AT 14:38:03 ON 04 SEP 2001
                E NEURODEGENERATIVE DISEASE/CT 5
                E E3+ALL/CT
                E NEURODEGENERATIVE DISEASES/CT 5
                E E3+ALL/CT
L5            826 S E1

     FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE' ENTERED AT 14:39:39 ON 04 SEP 2001
L6              1 FILE MEDLINE
L7              3 FILE CAPLUS
L8              3 FILE BIOSIS
L9              4 FILE EMBASE
     TOTAL FOR ALL FILES
L10            11 S L4 AND (L5 OR NERVOUS SYSTEM(L)DEGENERAT? OR
NEURODEGENERAT?(
L11             8 DUP REM L10 (3 DUPLICATES REMOVED)
L12             1 FILE MEDLINE
L13            21 FILE CAPLUS
L14            16 FILE BIOSIS
L15            31 FILE EMBASE
     TOTAL FOR ALL FILES
L16            69 S (ALZHEIMER? OR PARKINSON?) AND L4
L17             1 FILE MEDLINE
L18            21 FILE CAPLUS
L19            14 FILE BIOSIS
L20            27 FILE EMBASE
     TOTAL FOR ALL FILES
L21            63 S L16 NOT L10
L22            57 DUP REM L21 (6 DUPLICATES REMOVED)

=> select hit
ENTER ANSWER SET OR SMARTSELECT L# OR (L22):17
ENTER ANSWER NUMBER OR RANGE (1-):1-3
ENTER DISPLAY CODE (TI) OR ?:rn
```

E1 THROUGH E42 ASSIGNED

=> fil reg;s e1-42

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	412.03	1647.38

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-13.52	-90.24

FILE 'REGISTRY' ENTERED AT 14:47:20 ON 04 SEP 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

STRUCTURE FILE UPDATES: 3 SEP 2001 HIGHEST RN 354528-22-6
DICTIONARY FILE UPDATES: 3 SEP 2001 HIGHEST RN 354528-22-6

TSCA INFORMATION NOW CURRENT THROUGH January 11, 2001

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Structure search limits have been increased. See HELP SLIMIT for details.

1 147700-11-6/BI
(147700-11-6/RN)
1 340020-84-0/BI
(340020-84-0/RN)
1 340020-85-1/BI
(340020-85-1/RN)
1 340020-86-2/BI
(340020-86-2/RN)
1 340020-87-3/BI
(340020-87-3/RN)
1 340020-88-4/BI
(340020-88-4/RN)
1 340020-89-5/BI
(340020-89-5/RN)
1 340020-90-8/BI
(340020-90-8/RN)
1 340020-92-0/BI
(340020-92-0/RN)
1 340020-94-2/BI
(340020-94-2/RN)
1 340021-02-5/BI
(340021-02-5/RN)
1 340021-96-7/BI
(340021-96-7/RN)
1 340022-14-2/BI
(340022-14-2/RN)
1 340022-15-3/BI

(340022-15-3/RN)
1 340022-16-4/BI
(340022-16-4/RN)
1 340022-83-5/BI
(340022-83-5/RN)
1 340022-85-7/BI
(340022-85-7/RN)
1 340022-86-8/BI
(340022-86-8/RN)
1 340022-88-0/BI
(340022-88-0/RN)
1 340023-05-4/BI
(340023-05-4/RN)
1 340023-07-6/BI
(340023-07-6/RN)
1 340023-22-5/BI
(340023-22-5/RN)
1 340025-91-4/BI
(340025-91-4/RN)
1 340163-15-7/BI
(340163-15-7/RN)
1 340163-16-8/BI
(340163-16-8/RN)
1 340163-17-9/BI
(340163-17-9/RN)
1 340163-18-0/BI
(340163-18-0/RN)
1 340163-49-7/BI
(340163-49-7/RN)
1 340163-51-1/BI
(340163-51-1/RN)
1 340163-53-3/BI
(340163-53-3/RN)
1 340163-96-4/BI
(340163-96-4/RN)
1 340163-97-5/BI
(340163-97-5/RN)
1 340163-98-6/BI
(340163-98-6/RN)
1 340163-99-7/BI
(340163-99-7/RN)
1 340164-00-3/BI
(340164-00-3/RN)
1 340164-01-4/BI
(340164-01-4/RN)
1 340164-26-3/BI
(340164-26-3/RN)
1 340164-27-4/BI
(340164-27-4/RN)
1 340164-28-5/BI
(340164-28-5/RN)
1 340164-33-2/BI
(340164-33-2/RN)
1 340255-31-4/BI
(340255-31-4/RN)

```
             1 340266-61-7/BI
               (340266-61-7/RN)
L23         42 (147700-11-6/BI OR 340020-84-0/BI OR 340020-85-1/BI OR
340020-86
               -2/BI OR 340020-87-3/BI OR 340020-88-4/BI OR 340020-89-5/BI OR
               340020-90-8/BI OR 340020-92-0/BI OR 340020-94-2/BI OR
340021-02-
               5/BI OR 340021-96-7/BI OR 340022-14-2/BI OR 340022-15-3/BI OR
               340022-16-4/BI OR 340022-83-5/BI OR 340022-85-7/BI OR
340022-86-
               8/BI OR 340022-88-0/BI OR 340023-05-4/BI OR 340023-07-6/BI OR
               340023-22-5/BI OR 340025-91-4/BI OR 340163-15-7/BI OR
340163-16-
               8/BI OR 340163-17-9/BI OR 340163-18-0/BI OR 340163-49-7/BI OR
               340163-51-1/BI OR 340163-53-3/BI OR 340163-96-4/BI OR
340163-97-
               5/BI OR 340163-98-6/BI OR 340163-99-7/BI OR 340164-00-3/BI OR
               340164-01-4/BI OR 340164-26-3/BI OR 340164-27-4/BI OR
340164-28-
               5/BI OR 340164-33-2/BI OR 340255-31-4/BI OR 340266-61-7/BI)

=> d 1-3 9 20 21 24 31 33 42 ide cbib

L23  ANSWER 1 OF 42  REGISTRY  COPYRIGHT 2001 ACS
RN   340266-61-7  REGISTRY
CN   1H-Purine-2,6-dione,
8-(3-exo)-8-azabicyclo[3.2.1]oct-3-yl-3,7-dihydro-1,3-
     dipropyl-, mono(trifluoroacetate) (9CI)  (CA INDEX NAME)
FS   STEREOSEARCH
MF   C18 H27 N5 O2 . C2 H F3 O2
SR   CA
LC   STN Files:   CA, CAPLUS

     CM   1

     CRN  340266-60-6
     CMF  C18 H27 N5 O2

Relative stereochemistry.
```




```
     CM   2
```

CRN 76-05-1
CMF C2 H F3 O2



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:366887 Preparation of 8-substituted xanthines as adenosine receptor antagonists. Dowling, James E.; Ensinger, Carol; Kumaravel, Gnanasambandam; Petter, Russell C. (Biogen, Inc., USA). PCT Int. Appl. WO 2001034604 A2 20010517, 61 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2000-US31100 20001113. PRIORITY: US 1999-PV165283 19991112.

L23 ANSWER 2 OF 42 REGISTRY COPYRIGHT 2001 ACS
RN **340255-31-4** REGISTRY
CN 8-Azabicyclo[3.2.1]octane-8-carboxylic acid, 3-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)-, ethyl ester, (3-endo)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C21 H31 N5 O4
SR CA
LC STN Files: CA, CAPLUS

Relative stereochemistry.



1 REFERENCES IN FILE CA (1967 TO DATE)

1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:366887 Preparation of 8-substituted xanthines as adenosine receptor antagonists. Dowling, James E.; Ensinger, Carol; Kumaravel, Gnanasambandam; Petter, Russell C. (Biogen, Inc., USA). PCT Int. Appl. WO 2001034604 A2 20010517, 61 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2000-US31100 20001113. PRIORITY: US 1999-PV165283 19991112.

L23 ANSWER 3 OF 42 REGISTRY COPYRIGHT 2001 ACS
RN **340164-33-2** REGISTRY
CN 8-Azabicyclo[3.2.1]oct-2-ene-8-carboxylic acid, 3-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)-, ethyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C21 H29 N5 O4
SR CA
LC STN Files: CA, CAPLUS



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:366887 Preparation of 8-substituted xanthines as adenosine receptor antagonists. Dowling, James E.; Ensinger, Carol; Kumaravel, Gnanasambandam; Petter, Russell C. (Biogen, Inc., USA). PCT Int. Appl. WO 2001034604 A2 20010517, 61 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN:

PIXXD2. APPLICATION: WO 2000-US31100 20001113. PRIORITY: US 1999-PV165283 19991112.

L23 ANSWER 9 OF 42 REGISTRY COPYRIGHT 2001 ACS
RN **340163-99-7** REGISTRY
CN 1H-Purine-2,6-dione, 3,7-dihydro-8-(8-oxabicyclo[3.2.1]oct-3-yl)-1,3-dipropyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C18 H26 N4 O3
SR CA
LC STN Files: CA, CAPLUS



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:366887 Preparation of 8-substituted xanthines as adenosine receptor antagonists. Dowling, James E.; Ensinger, Carol; Kumaravel, Gnanasambandam; Petter, Russell C. (Biogen, Inc., USA). PCT Int. Appl. WO 2001034604 A2 20010517, 61 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2000-US31100 20001113. PRIORITY: US 1999-PV165283 19991112.

L23 ANSWER 20 OF 42 REGISTRY COPYRIGHT 2001 ACS
RN **340025-91-4** REGISTRY
CN 1H-Purine-2,6-dione, 3,7-dihydro-8-[4-[[[(4-methylphenyl)sulfonyl]oxy]methyl]-2-oxabicyclo[2.2.2]oct-1-yl]-1,3-dipropyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C26 H34 N4 O6 S
SR CA
LC STN Files: CA, CAPLUS



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:366889 Preparation of polycycloalkylpurines as adenosine receptor antagonists. Kiesman, William F.; Dowling, James E.; Ensinger, Carol L.; Kumaravel, Gnanasambandam; Petter, Russell C.; Chang, He Xi; Lin, Ko Chung (Biogen, Inc., USA). PCT Int. Appl. WO 2001034610 A1 20010517, 124 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2000-US31058 20001113. PRIORITY: US 1999-PV165191 19991112.

L23 ANSWER 21 OF 42 REGISTRY COPYRIGHT 2001 ACS
RN **340023-22-5** REGISTRY
CN 2-Oxabicyclo[2.2.2]octane-1-carboxaldehyde, 4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C19 H26 N4 O4
SR CA
LC STN Files: CA, CAPLUS



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:366889 Preparation of polycycloalkylpurines as adenosine receptor antagonists. Kiesman, William F.; Dowling, James E.; Ensinger, Carol L.; Kumaravel, Gnanasambandam; Petter, Russell C.; Chang, He Xi; Lin, Ko Chung (Biogen, Inc., USA). PCT Int. Appl. WO 2001034610 A1 20010517, 124 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2000-US31058 20001113. PRIORITY: US 1999-PV165191 19991112.

L23 ANSWER 24 OF 42 REGISTRY COPYRIGHT 2001 ACS
RN **340022-88-0** REGISTRY
CN Acetic acid, [[hexahydro-6a-[2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-7-(tetrahydro-2H-pyran-2-yl)-1H-purin-8-yl]-2,5-methanofuro[3,2-b]furan-3-yl]oxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)
MF C29 H42 N4 O8
SR CA
LC STN Files: CA, CAPLUS



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:366889 Preparation of polycycloalkylpurines as adenosine receptor antagonists. Kiesman, William F.; Dowling, James E.; Ensinger, Carol L.; Kumaravel, Gnanasambandam; Petter, Russell C.; Chang, He Xi; Lin, Ko Chung (Biogen, Inc., USA). PCT Int. Appl. WO 2001034610 A1 20010517, 124 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2000-US31058 20001113. PRIORITY: US 1999-PV165191 19991112.

L23 ANSWER 31 OF 42 REGISTRY COPYRIGHT 2001 ACS
RN **340021-96-7** REGISTRY
CN 2-Oxabicyclo[2.2.2]octane-1-propanoic acid, 4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C21 H30 N4 O5
SR CA
LC STN Files: CA, CAPLUS



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:366889 Preparation of polycycloalkylpurines as adenosine receptor antagonists. Kiesman, William F.; Dowling, James E.; Ensinger, Carol L.; Kumaravel, Gnanasambandam; Petter, Russell C.; Chang, He Xi; Lin, Ko Chung (Biogen, Inc., USA). PCT Int. Appl. WO 2001034610 A1 20010517, 124 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2000-US31058 20001113. PRIORITY: US 1999-PV165191 19991112.

L23 ANSWER 33 OF 42 REGISTRY COPYRIGHT 2001 ACS
RN **340020-94-2** REGISTRY
CN Acetic acid,
[[hexahydro-6a-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)-2,5-methanofuro[3,2-b]furan-3-yl]oxy]- (9CI) (CA INDEX NAME)
MF C20 H26 N4 O7
SR CA
LC STN Files: CA, CAPLUS



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:366889 Preparation of polycycloalkylpurines as adenosine receptor antagonists. Kiesman, William F.; Dowling, James E.; Ensinger, Carol L.; Kumaravel, Gnanasambandam; Petter, Russell C.; Chang, He Xi; Lin, Ko Chung (Biogen, Inc., USA). PCT Int. Appl. WO 2001034610 A1 20010517, 124 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2000-US31058 20001113. PRIORITY: US 1999-PV165191 19991112.

L23 ANSWER 42 OF 42 REGISTRY COPYRIGHT 2001 ACS
RN **147700-11-6** REGISTRY
CN 1H-Purine-2,6-dione,
8-[(1E)-2-(3-chlorophenyl)ethenyl]-3,7-dihydro-1,3,7-trimethyl- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1H-Purine-2,6-dione, 8-[2-(3-chlorophenyl)ethenyl]-3,7-dihydro-1,3,7-trimethyl-, (E)-
OTHER NAMES:
CN 8-(3-Chlorostyryl)caffeine
FS STEREOSEARCH
MF C16 H15 Cl N4 O2
SR CA
LC STN Files: BIOSIS, CA, CAPLUS, CHEMCATS, TOXLIT, USPATFULL

Double bond geometry as shown.



27 REFERENCES IN FILE CA (1967 TO DATE)
28 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:217597 Leptin for use in inhibition of endothelial cell proliferation optionally together with VEGF inhibitors. Rubinstein, Menachem; Cohen, Batya; Barkan, Dalit (Yeda Research and Development Co. Ltd., Israel). PCT Int. Appl. WO 2001018040 A2 20010315, 38 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ,

CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 2000-IL525 20000904. PRIORITY: IL 1999-131739 19990905; IL 1999-132312 19991010.

REFERENCE 2: 134:217113 Effect of the adenosine A2A-receptors on the brain stability with respect to complete global cerebral ischemia. Kulinskii, V. I.; Minakina, L. N.; Usov, L. A. (Departments of Biochemistry and Pharmacology, Irkutsk Medical University, Irkutsk, 664003, Russia). Eksp. Klin. Farmakol., 63(6), 9-11 (Russian) 2000. CODEN: EKFAE9. ISSN: 0869-2092. Publisher: Izdatel'stvo Folium.

REFERENCE 3: 133:346544 Further characterization of a CNS adenosine A2a receptor ligand [11C]KF18446 with in vitro autoradiography and in vivo tissue uptake. Ishiwata, Kiichi; Ogi, Nobuo; Shimada, Junichi; Nonaka, Hiromi; Tanaka, Akira; Suzuki, Fumio; Senda, Michio (Positron Medical Center, Tokyo Metropolitan Institute of Gerontology, Tokyo, 173-0022, Japan). Ann. Nucl. Med., 14(2), 81-89 (English) 2000. CODEN: ANMEEX. ISSN: 0914-7187. Publisher: Japanese Society of Nuclear Medicine.

REFERENCE 4: 133:171773 Structure-activity relationships for G2 checkpoint inhibition by caffeine analogs. Jiang, Xiuxian; Lim, Lynette Y.; Daly, John W.; Li, An Hu; Jacobson, Kenneth A.; Roberge, Michel (Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, BC, V6T 1Z3, Can.). Int. J. Oncol., 16(5), 971-978 (English) 2000. CODEN: IJONES. ISSN: 1019-6439. Publisher: International Journal of Oncology.

REFERENCE 5: 133:53618 Adenosine receptor antagonists induce persistent bursting in the rat hippocampal CA3 region via an NMDA receptor-dependent mechanism. Thummler, Susanne; Dunwiddie, Thomas V. (Institut fur Pharmakologie und Toxikologie, Universitat Leipzig, Leipzig, D04107, Germany). J. Neurophysiol., 83(4), 1787-1795 (English) 2000. CODEN: JONEA4. ISSN: 0022-3077. Publisher: American Physiological Society.

REFERENCE 6: 132:103171 Effects of adenosine and .gamma.-aminobutyric acid A receptor antagonists on N-methyl-D-aspartate induced neurotoxicity in the rat hippocampus. Robledo, Patricia; Ursu, Gloria; Mahy, Nicole (Unitat de Neuroquimica, Universidad de Barcelona, Barcelona, 08036, Spain). Hippocampus, 9(5), 527-533 (English) 1999. CODEN: HIPPEL. ISSN: 1050-9631. Publisher: Wiley-Liss, Inc..

REFERENCE 7: 132:30665 Role of adenosine and N-methyl-D-aspartate receptors in mediating haloperidol-induced gene expression and catalepsy. Chartoff, Elena H.; Ward, Raymond P.; Dorsa, Daniel M. (Program in Neurobiology and Behavior, University of Washington, Seattle, WA, USA). J. Pharmacol. Exp.

Ther., 291(2), 531-537 (English) 1999. CODEN: JPETAB. ISSN: 0022-3565. Publisher: American Society for Pharmacology and Experimental Therapeutics.

REFERENCE 8: 132:347 Autoradiographic comparison of the potency of several structurally unrelated adenosine receptor antagonists at adenosine A1 and A2A receptors. Fredholm, Bertil B.; Lindstrom, Karin (Department of Physiology and Pharmacology, Section of Molecular Neuropharmacology, Karolinska Institutet, Stockholm, S-171 77, Swed.). Eur. J. Pharmacol., 380(2/3), 197-202 (English) 1999. CODEN: EJPHAZ. ISSN: 0014-2999. Publisher: Elsevier Science B.V..

REFERENCE 9: 131:96959 Comparative molecular field analysis (CoMFA) of a series of selective adenosine receptor A2A antagonists. Baraldi, Pier Giovanni; Borea, Pier Andrea; Bergonzoni, Manuela; Cacciari, Barbara; Ongini, Ennio; Recanatini, Maurizio; Spalluto, Giampiero (Dipartimento di Scienze Farmaceutiche, Universita di Ferrara, Ferrara, 44100, Italy). Drug Dev. Res., 46(2), 126-133 (English) 1999. CODEN: DDREDK. ISSN: 0272-4391. Publisher: Wiley-Liss, Inc..

REFERENCE 10: 130:306595 Methods for reducing ischemic injury of the heart via the sequential administration of synergistic cardioprotective agents. Liang, Bruce T.; Jacobson, Kenneth A. (Trustees of the University of Pennsylvania, USA; National Institute of Health). PCT Int. Appl. WO 9920284 A1 19990429, 48 pp. DESIGNATED STATES: W: AU, CA, JP, US; RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE. (English). CODEN: PIXXD2. APPLICATION: WO 1998-US22515 19981023. PRIORITY: US 1997-62737 19971023.

```
=> fil medl,caplus,biosis,embase;s shimada, ?/au;s suzuki f?/au
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    31.25    1678.63

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00     -90.24

FILE 'MEDLINE' ENTERED AT 14:49:13 ON 04 SEP 2001

FILE 'CAPLUS' ENTERED AT 14:49:13 ON 04 SEP 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 14:49:13 ON 04 SEP 2001
COPYRIGHT (C) 2001 BIOSIS(R)

FILE 'EMBASE' ENTERED AT 14:49:13 ON 04 SEP 2001
COPYRIGHT (C) 2001 Elsevier Science B.V.  All rights reserved.


L24       7435 FILE MEDLINE
L25      16781 FILE CAPLUS
```

```
L26        9269 FILE BIOSIS
L27        6349 FILE EMBASE

TOTAL FOR ALL FILES
L28       39834 SHIMADA, ?/AU


L29         725 FILE MEDLINE
L30        1346 FILE CAPLUS
L31         951 FILE BIOSIS
L32         608 FILE EMBASE

TOTAL FOR ALL FILES
L33        3630 SUZUKI F?/AU

=> s l28 and l33
L34          21 FILE MEDLINE
L35          66 FILE CAPLUS
L36          26 FILE BIOSIS
L37          22 FILE EMBASE

TOTAL FOR ALL FILES
L38         135 L28 AND L33

=> s l38 and (alzheimer? or parkinson? or l5 or nervous system(l)degenerat?
or neurodegenerat?(2a)(disease? or disorder?))
L39           1 FILE MEDLINE
L40           8 FILE CAPLUS
L41           2 FILE BIOSIS
L42           1 FILE EMBASE

TOTAL FOR ALL FILES
L43          12 L38 AND (ALZHEIMER? OR PARKINSON? OR L5 OR NERVOUS SYSTEM(L)
                DEGENERAT? OR NEURODEGENERAT?(2A)(DISEASE? OR DISORDER?))

=> s l43 not (l10 or l16)
L44           1 FILE MEDLINE
L45           2 FILE CAPLUS
L46           2 FILE BIOSIS
L47           0 FILE EMBASE

TOTAL FOR ALL FILES
L48           5 L43 NOT (L10 OR L16)

=> dup rem l48
PROCESSING COMPLETED FOR L48
L49           4 DUP REM L48 (1 DUPLICATE REMOVED)

=> d cbib abs 1-4

L49  ANSWER 1 OF 4  CAPLUS  COPYRIGHT 2001 ACS
1998:672551   Document No. 129:275928  Preparation of [1,2,4]triazolo[1,5-
     c]pyrimidine derivatives as adenosine A2A receptor antagonists.  Tsumuki,
     Hiroshi; Shimada, Junichi; Imma, Hironori; Nakamura, Akiko;
     Nonaka, Hiromi; Shiozaki, Shizuo; Ichikawa, Shunji; Kanda, Tomoyuki;
```

Kuwana, Yoshihisa; Ichimura, Michio; **Suzuki, Fumio** (Kyowa Hakko Kogyo Co., Ltd., Japan; et al.). PCT Int. Appl. WO 9842711 A1 19981001, 210 pp. DESIGNATED STATES: W: AU, BG, BR, CA, CN, CZ, HU, IL, JP, KR, MX, NO, NZ, PL, RO, SG, SI, SK, UA, US, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE. (Japanese). CODEN: PIXXD2. APPLICATION: WO 1998-JP1266 19980324. PRIORITY: JP 1997-69566 19970324.

GI



I

AB The title compds. [I; R1 is (un)substituted aryl or the like; R2 is H halo, lower alkyl, (un)substituted aryl, or the like; R3 is H, halo, XR10, etc.; X is O or S; R10 is (un)substituted aryl, heteroaryl, or aralkyl, lower alkyl, etc.; Q is H, 3,4-dimethoxybenzyl] are prepd. I, possessing adenosine A2A receptor antagonism, are useful for prevention and treatment of various diseases due to the hyperactivity of adenosine A2A receptors (such as **Parkinson**'s disease and senile dementia). Thus, N-(2-furoyl)-N'-(2-methylthio-4-phenoxypyrimidin-6-yl)hydrazine (prepn. given) was reacted with P2O5 and (TMS)2NH and then with veratrylamine to give 62% I (R1 = 2-furanyl, R2 = H, R3 = phenoxy, Q = veratryl). I were tested and showed adenosine A2A receptor antagonism activity and the effect for **Parkinson**'s disease. A formulation contg. I was also prepd.

L49 ANSWER 2 OF 4 BIOSIS COPYRIGHT 2001 BIOSIS

1996:383738 Document No.: PREV199699106094. Carbon-11-labeled KF15372: A potential central nervous system adenosine A-1 receptor ligand. Furuta, Riko; Ishiwata, Kiichi (1); Kiyosawa, Motohiro; Ishii, Shin-Ichi; Saito, Noriko; **Shimada, Jun-Ichi**; Endo, Kazutoyo; **Suzuki, Fumio** ; Senda, Michio. (1) Positron Med. Cent., Tokyo Metropolitan Inst. Gerontol., 1-1 Naka-cho, Itabashi, Tokyo 173 Japan. Journal of Nuclear Medicine, (1996) Vol. 37, No. 7, pp. 1203-1207. ISSN: 0161-5505.

Language:
English.

AB The carbon-11-labeled selective adenosine A-1 antagonist KF15372 ((1-propyl-11C)8-dicyclopropylmethyl-1,3-dipropylxanthine) was evaluated in vivo as a PET ligand for mapping CNS adenosine Al receptors. Methods: The regional brain distribution of (11C)KF15372 and the effects of adenosine antagonists on the distribution were determined in mice by tissue sampling. In rats, in which the retinal projection fibres to the superior colliculus had degenerated due to unilateral eye removal, the brain distribution of (11C)KF15372 was visualized by ex vivo autoradiography. Results: The mouse brain uptake of (11C)KF15372 was 1.8% i.d./g at 5 min and then it gradually decreased. The uptake was high in

the hippocampus, cerebral cortex, striatum and cerebellum, and was significantly reduced by A-1 antagonists but not by A-2 antagonists. The brain distribution of 11C assessed by the tissue sampling and autoradiography was compatible with that of the A-1 receptors. Autoradiography clearly visualized unilaterally decreased A-1 receptor binding in the superior colliculus. Conclusion: The results demonstrated that (11C)KF15372 is a selective and high-affinity adenosine A-1 receptor ligand and is useful for detecting the degeneration of presynaptic neurons.

L49 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2001 ACS
1995:501359 Document No. 122:248318 Remedy for **Parkinson**'s disease. **Suzuki, Fumio; Shimada, Junichi;** Koike, Nobuaki; Ichikawa, Shunji; Nakamura, Joji; Kanda, Tomoyuki; Kitamura, Shigeto (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. WO 9503806 A1 19950209, 27 pp. DESIGNATED STATES: W: AU, CA, JP, KR, NO, US; RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE. (Japanese). CODEN: PIXXD2. APPLICATION: WO 1994-JP1196 19940720. PRIORITY: JP 1993-184295 19930727.

AB A remedy for **Parkinson**'s disease contains a polycyclic compd., i.e. [1,2,4]-triazino[1,5-a]-1,3,5-triazines and 1,2,4-triazo[1,5-c]quinazolines. For example, 7-amino-2-(2-furyl)-5-phenoxy-[1,2,4]-triazino[1,5-a]-1,3,5-triazine was tested for spontaneous motion control effects with **Parkinson**'s disease mouse models. Also, formulations contg. the active ingredients are provided.

L49 ANSWER 4 OF 4 MEDLINE DUPLICATE 1
94320609 Document Number: 94320609. PubMed ID: 8045270. KF17837: a novel selective adenosine A2A receptor antagonist with anticataleptic activity. Kanda T; Shiozaki S; **Shimada J; Suzuki F;** Nakamura J. (Pharmaceutical Research Laboratories, Kyowa Hakko Kogyo Co. Ltd., Shizuoka, Japan.) EUROPEAN JOURNAL OF PHARMACOLOGY, (1994 May 2) 256 (3) 263-8. Journal code: EN6; 1254354. ISSN: 0014-2999. Pub. country: Netherlands. Language: English.

AB KF17837 is a novel selective adenosine A2A receptor antagonist. Oral administration of KF17837 (2.5, 10.0 and 30.0 mg/kg) significantly ameliorated the cataleptic responses induced by intracerebroventricular administration of an adenosine A2A receptor agonist, CGS 21680 (10 micrograms), in a dose-dependent manner. KF17837 also reduced the catalepsy induced by haloperidol (1 mg/kg i.p.) and by reserpine (5 mg/kg i.p.). These anticataleptic effects were exhibited dose dependently at doses from 0.625 and 2.5 mg/kg p.o., respectively. Moreover, KF17837 (0.625 mg/kg p.o.) potentiated the anticataleptic effects of a subthreshold dose of L-3,4-dihydroxyphenylalanine (L-DOPA; 25 mg/kg i.p.) plus benserazide (6.25 mg/kg i.p.). These results suggested that KF17837 is a centrally active adenosine A2A receptor antagonist and that the dopaminergic function of the nigrostriatal pathway is potentiated by adenosine A2A receptor antagonists. Furthermore, KF17837 may be a useful drug in the treatment of **parkinsonism**.

=> del his y

=> fil reg
COST IN U.S. DOLLARS SINCE FILE TOTAL